<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03233035</url>
  </required_header>
  <id_info>
    <org_study_id>Ket-Int-Nas-TR</org_study_id>
    <nct_id>NCT03233035</nct_id>
  </id_info>
  <brief_title>Low Dose Ketamine Intra Nasal Traumatology</brief_title>
  <acronym>Ket</acronym>
  <official_title>Intranasal Ketamine for Treatment of Acute Pain in the Emergency Department : A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Monastir</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Monastir</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of early administration of low-dose intranasal ketamine&#xD;
      analgesic agents in patients with moderate to severe pain in the ED in reducing the need for&#xD;
      opioid or non opioids analgesic agents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intranasal ketamine for treatment of acute pain in the emergency department : A randomized&#xD;
      controlled trial&#xD;
&#xD;
      Introduction :&#xD;
&#xD;
      Pain is the most common complaint for emergency department (ED) visits [1].The provision of&#xD;
      adequate, safe, and timely analgesia is a core component of patient care in the emergency&#xD;
      department (ED). Ketamine is a noncompetitive Nmethyl- D-aspartate and glutamate receptor&#xD;
      antagonist that decreases central sensitization, &quot;wind-up&quot; phenomena, and pain memory [2,3].&#xD;
&#xD;
      At subdissociative doses (0.1 to 0.6 mg/kg; most commonly 0.3 mg/kg) maintains potent&#xD;
      analgesic and amnestic effects that are accompanied by preservation of protective airway&#xD;
      reflexes, spontaneous respiration, and cardiopulmonary stability [4-6].&#xD;
&#xD;
      Intranasal route ….&#xD;
&#xD;
      Objective of the study :&#xD;
&#xD;
      To evaluate the efficacy and safety of early administration of low-dose intranasal ketamine&#xD;
      analgesic agents in patients with moderate to severe pain in the ED in reducing the need for&#xD;
      opioid or class III analgesic agents.&#xD;
&#xD;
      Materials and Methods :&#xD;
&#xD;
      Study design :&#xD;
&#xD;
      It is a ramdomized, prospective, double blind, controlled, multicentric trial. The study is&#xD;
      registered with clinical.tria.gov (…….).&#xD;
&#xD;
      Study Setting and Selection of Participants :&#xD;
&#xD;
      The trial is conducted in three community teaching hospitals :&#xD;
&#xD;
        -  Emergency department, fattouma bourguiba university hospital, monastir, tunisia&#xD;
&#xD;
        -  Emergency department, sahloul university hospital, sousse, tunisia&#xD;
&#xD;
        -  Emergency department, farhat hached university hospital, sousse, tunisia&#xD;
&#xD;
      ED principal investigators maintain the randomization list, which is generated before the&#xD;
      start of the study, prepare the medication, and deliver it to the treating physician in a&#xD;
      blinded manner.&#xD;
&#xD;
      Inclusion criteria :&#xD;
&#xD;
      The study includes patients aged 18 to 80 years who presented to the ED with acute limb&#xD;
      trauma pain with a visual analogue scale (VAS) of 5 or more on a standard 11- point (0 to&#xD;
      10). An informed consent is necessary.&#xD;
&#xD;
      Exclusion criteria :&#xD;
&#xD;
        -  Pregnancy,&#xD;
&#xD;
        -  Breast-feeding,&#xD;
&#xD;
        -  Altered mental status,&#xD;
&#xD;
        -  Allergy to ketamine or morphine or&#xD;
&#xD;
        -  Weight less than 46 kg or greater than 115 kg,&#xD;
&#xD;
        -  Unstable vital signs (systolic blood pressure &lt;90 or &gt;180 mm Hg, pulse rate &lt;50 or &gt;150&#xD;
           beats/min, and respiration rate &lt;10 or &gt;30 breaths/min),&#xD;
&#xD;
        -  Medical history of acute head or eye injury, seizure, intracranial hypertension, chronic&#xD;
           pain, severre renal or hepatic insufficiency,&#xD;
&#xD;
        -  Alcohol or drug abuse,&#xD;
&#xD;
        -  Psychiatric illness,&#xD;
&#xD;
        -  Recent (4 hours before) analgesic agent use.&#xD;
&#xD;
      Protocol :&#xD;
&#xD;
      In the triage area, each patient having the inclusion criteria receives 25mg of ketamine in&#xD;
      0.5 ml of serum saline in one pulverisation per nostril or 0.5 mL of normal saline solution&#xD;
      in one pulverisation per nostril as a placebo according to the predetermined randomization&#xD;
      list. None of the treating physician or nurses is aware about the medication received. In all&#xD;
      patients included, the investigators collect vital signs ; demographic and clinical data.&#xD;
&#xD;
      Study investigators record VAS, and adverse effects at 15, 30, 60, 90, and 120 minutes.&#xD;
&#xD;
      At 30 minutes, if patients report a pain numeric rating scale score of 5 or greater and&#xD;
      request additional pain relief, titrated morphine is administered as a rescue analgesic with&#xD;
      a dose of 0.1 mg/Kg repeated every 3 to 5 minutes if the pain numeric rating scale score is&#xD;
      still greater or equal to 3.&#xD;
&#xD;
      All data recorded on data collection sheets, including sex, demographics, medical history,&#xD;
      and vital signs, were entered into SPSS (version 20.0; IBM Corp) by the research manager.&#xD;
&#xD;
      Patients's informed consent is obtained. The ethic commitee of our institution approved the&#xD;
      study.&#xD;
&#xD;
      Endpoints :&#xD;
&#xD;
      Primary endpoints :&#xD;
&#xD;
      - Need for rescue opioids during ED stay&#xD;
&#xD;
      Secondary endpoints :&#xD;
&#xD;
        -  requirement of non-opioids analgesic agents.&#xD;
&#xD;
        -  percentage of patients discharged from the ED with VAS &lt;30.&#xD;
&#xD;
        -  Safety : adverse events&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">December 1, 2018</completion_date>
  <primary_completion_date type="Actual">December 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double Blind Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Ketamine versus placebo as a double blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number and percentage of patients who need rescue opiods in the two groups</measure>
    <time_frame>30 minutes</time_frame>
    <description>the need for rescue opioids during ED stay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intolerance to treatement and adverse events</measure>
    <time_frame>30 minutes and at 120 minutes</time_frame>
    <description>Noticing any sign of intolerance due to treatement : Dizziness , Vomiting..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with VAS &lt;30 mm at discharge</measure>
    <time_frame>120 minutes</time_frame>
    <description>percentage of patients discharged from the ED with VAS &lt;30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of patients who required non opiods analgesics</measure>
    <time_frame>30 minutes</time_frame>
    <description>Requirement of non-opioids analgesic agents</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1102</enrollment>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intranasal placebo pulverisation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intranasal ketamine pulverisation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received</description>
    <arm_group_label>Ketamine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5 mL of normal saline solution as a placebo in one pulverisation per nostril</description>
    <arm_group_label>placebo group</arm_group_label>
    <other_name>normal saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The study includes patients aged 18 to 80 years who presented to the ED with acute&#xD;
             limb trauma pain with a visual analgesic scale (VAS) of 5 or more on a standard 11-&#xD;
             point (0 to 10). An informed consent is necessary.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Pregnancy,&#xD;
&#xD;
          -  Breast-feeding,&#xD;
&#xD;
          -  Altered mental status,&#xD;
&#xD;
          -  Allergy to ketamine or morphine or&#xD;
&#xD;
          -  Weight less than 46 kg or greater than 115 kg,&#xD;
&#xD;
          -  Unstable vital signs (systolic blood pressure &lt;90 or &gt;180 mm Hg, pulse rate &lt;50 or&#xD;
             &gt;150 beats/min, and respiration rate &lt;10 or &gt;30 breaths/min),&#xD;
&#xD;
          -  Medical history of acute head or eye injury, seizure, intracranial hypertension,&#xD;
             chronic pain, severre renal or hepatic insufficiency,&#xD;
&#xD;
          -  Alcohol or drug abuse,&#xD;
&#xD;
          -  Psychiatric illness,&#xD;
&#xD;
          -  Recent (4 hours before) analgesic agent use.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nouira Semir, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>university Hospital of Monastir</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nouira Samir</name>
      <address>
        <city>Monastir</city>
        <state>Emergency Department Monastir, Tunisia 5000</state>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency department of university hospital Fattouma Bourguiba of Monastir</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 14, 2017</study_first_submitted>
  <study_first_submitted_qc>July 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2017</study_first_posted>
  <last_update_submitted>June 30, 2019</last_update_submitted>
  <last_update_submitted_qc>June 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Monastir</investigator_affiliation>
    <investigator_full_name>Pr. Semir Nouira</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Ketamine-Intranasal-Acute pain-Emergency departement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

